[{"address1": "180 North LaSalle Street", "address2": "Suite 1600", "city": "Chicago", "state": "IL", "zip": "60601", "country": "United States", "phone": "844 445 5704", "website": "https://www.xerispharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 377, "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul R. Edick", "age": 67, "title": "Chairman & CEO", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1206766, "exercisedValue": 0, "unexercisedValue": 590310}, {"maxAge": 1, "name": "Mr. John P. Shannon", "age": 61, "title": "President & COO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 918153, "exercisedValue": 0, "unexercisedValue": 148377}, {"maxAge": 1, "name": "Mr. Steven M. Pieper", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 681142, "exercisedValue": 0, "unexercisedValue": 15586}, {"maxAge": 1, "name": "Ms. Beth P. Hecht J.D.", "age": 59, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 695443, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth E. Johnson Pharm. D., Pharm.D.", "age": 60, "title": "Senior VP of Global Development & Medical Affairs", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 596967, "exercisedValue": 0, "unexercisedValue": 31173}, {"maxAge": 1, "name": "Ms. Allison  Wey", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  McCulloch", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.86, "open": 1.9, "dayLow": 1.84, "dayHigh": 1.93, "regularMarketPreviousClose": 1.86, "regularMarketOpen": 1.9, "regularMarketDayLow": 1.84, "regularMarketDayHigh": 1.93, "beta": 1.105, "forwardPE": -8.590909, "volume": 1118354, "regularMarketVolume": 1118354, "averageVolume": 1873464, "averageVolume10days": 1139350, "averageDailyVolume10Day": 1139350, "bid": 1.87, "ask": 1.9, "bidSize": 600, "askSize": 600, "marketCap": 280200064, "fiftyTwoWeekLow": 1.46, "fiftyTwoWeekHigh": 3.26, "priceToSalesTrailing12Months": 1.7094334, "fiftyDayAverage": 2.2048, "twoHundredDayAverage": 2.1807, "currency": "USD", "enterpriseValue": 422197056, "profitMargins": -0.3798, "floatShares": 136519365, "sharesOutstanding": 148254000, "sharesShort": 8941067, "sharesShortPriorMonth": 9242895, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.060300004, "heldPercentInsiders": 0.03738, "heldPercentInstitutions": 0.41768003, "shortRatio": 5.86, "shortPercentOfFloat": 0.0618, "bookValue": -0.049, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -62255000, "trailingEps": -0.45, "forwardEps": -0.22, "enterpriseToRevenue": 2.576, "enterpriseToEbitda": -13.327, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XERS", "underlyingSymbol": "XERS", "shortName": "Xeris Biopharma Holdings, Inc.", "longName": "Xeris Biopharma Holdings, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8f5f7125-cc84-3c21-a68b-9d3090e24887", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.89, "targetHighPrice": 6.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.75, "targetMedianPrice": 4.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 72451000, "totalCashPerShare": 0.516, "ebitda": -31680000, "totalDebt": 229191008, "quickRatio": 1.173, "currentRatio": 1.642, "totalRevenue": 163914000, "revenuePerShare": 1.191, "returnOnAssets": -0.08246, "returnOnEquity": -3.2420301, "freeCashflow": -19622876, "operatingCashflow": -47023000, "revenueGrowth": 0.339, "grossMargins": 0.82524, "ebitdaMargins": -0.19327, "operatingMargins": -0.22169, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]